CYTH | tickerfilter.com

Fundamental analysis

21%

Profitability 0%

Dept financing 25%

Liquidity 27%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

2.80%

3 Months

4.43%

6 Months

-2.32%

1 Year

-48.89%

2 Year

-2.45%

Key data

Stock price

$0.72

P/E Ratio

0.00

DAY RANGE

$0.63 - $0.73

EPS

-$1.23

52 WEEK RANGE

$0.55 - $1.62

52 WEEK CHANGE

-$49.25

MARKET CAP

22.641 M

YIELD

N/A

SHARES OUTSTANDING

28.696 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

0.33

PUBLIC FLOAT

AVERAGE 10 VOLUME

N/A

AVERAGE 30 VOLUME

$54,143

Company detail

CEO: Scott Fine
Region: US
Website: cyclotherapeutics.com
Employees: 9
IPO year: 2007

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. In addition, it sells cyclodextrins and related products to pharmaceutical, nutritional, and other industries.

CYTH - Cyclo Therapeutics, Inc.